<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <meta http-equiv="X-UA-Compatible" content="ie=edge">
  <title>PolyQ - SCA17</title>
  <link rel="shortcut icon" href="../../Images/image1.ico">
  <link rel="stylesheet" href="style_2.css">
  <link rel="stylesheet" href="highlight-js/highlightjs.css">
  <link rel="stylesheet" href="ScrollSpy.css">
  <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/6.1.1/css/all.min.css" integrity="sha512-KfkfwYDsLkIlwQp6LFnl8zNdLGxu9YAA1QvwINks4PhcElQSvqcyVLLD9aMhXd13uQjoXtEKNosOWaZqXgel0g==" crossorigin="anonymous" referrerpolicy="no-referrer" />
  <link rel="stylesheet" href="int-image.css">
</head>
<body>
  <script src="ScrollSpy.min.js"></script>
  <script src="highlight-js/highlight.pack.js"></script>
    <header>
      <a href=""><img class="abcri-logo" src="../../Images/Logo_ABCRI.png"></a>
      <a><img class="mngt-logo" src="../../Images/Logo_MNGT.png"></a>
      <h1> <strong>A ABC Research Institute polyglutamine disease database</strong></h1>
    </header>
  <nav>
    <img class="poly-logo" src="../../Images/logo-plyq.png"/>
    <ul>
      <li><a href="../hd">HD</a></li>
      <li><a href="../drpla">DRPLA</a></li>
      <li><a href="../sbma">SBMA</a></li>
    </ul>
      <div class="dropdown">
        <button onclick="myFunction()" class="dropbtn">More <i class="fa-solid fa-caret-down"></i></button>
        <div class="dropdown-content" id="myDropdown">
          <a href="../sca1">SCA1</a>
          <a href="../sca2">SCA2</a>
          <a href="../sca3">SCA3</a>
          <a href="../sca6">SCA6</a>
          <a href="../sca7">SCA7</a>
        </div>
      </div>
      <div class="dropdown-little">
        <button onclick="myFunctionLittle()" class="dropbtn-little">Other Diseases &nbsp <i class="fa-solid fa-turn-down"></i></button>
        <div class="dropdown-content-little" id="myDropdownLittle">
          <a href="../hd">HD</a>
          <a href="../drpla">DRPLA</a>
          <a href="../sbma">SBMA</a>
          <a href="../sca1">SCA1</a>
          <a href="../sca2">SCA2</a>
          <a href="../sca3">SCA3</a>
          <a href="../sca6">SCA6</a>
          <a href="../sca7">SCA7</a>
        </div>
      </div>
    <a href="../../home" class="return-button"><i class="fa-solid fa-house"></i> Return to Home page </a>
    <a href="../../home" class="return-little"><i class="fa-solid fa-house"></i> Home </a>
  </nav>
  <main>
    <div class="aside-bar-left">
      <h3> Page navigation</h3>
      <div id="indicator"></div>
    </div>
    <div class="text">
    <h1><a href="./"><i class="fa-solid fa-caret-right"></i> &nbspSpinocerebellar Ataxia 17</a></h1>
    <section class="scrollspy" spy-title="Introduction">
      <div class="intro-section">
        <h2> Introduction </h2>
        <p>
          Spinocerebellar ataxia type 17 (SCA17) is a rare autosomal dominant neurodegenerative disease caused by a CAG repeat expansion in the TATA-box binding protein gene (TBP). Though the genetic abnormalities are mostly observed as a hereditary trait, de novo mutations have also been reported.
        </p>
        <p>
          The disease has a varied age at onset and clinical presentation. It is distinct from other SCAs for its association with dementia, psychiatric symptoms, and some patients presenting with chorea.
        </p>
        <p>
          SCA17 is inherited in an autosomal dominant manner. Offspring of affected heterozygous individuals are at a 50% risk of inheriting the expanded TBP allele. The age of onset, severity, specific symptoms, and progression of the disease are variable and cannot be precisely predicted by family history or size of expansion. Although most TBP mutations in SCA17 patients are inherited as an autosomal dominant trait, de novo mutations have also been reported <span class="refbig"><a href="#ref-one">[1]</a></span><span class="reflittle"><a href="#ref-one-little">[1]</a></span>.
        </p>
      </div>
    </section>
    <section class="scrollspy" spy-title="First described">
      <div class="firstd-section">
      <h2> First Described</h2>
      <p>
        In 1999, a polyglutamine expansion was identified in the transcription factor TATA-binding protein (TBP) in a patient with ataxia with negative family history <span class="refbig"><a href="#ref-one">[1]</a></span><span class="reflittle"><a href="#ref-one-little">[1]</a></span>. CAG/CAA repeat expansions in the TBP gene were identified in families with spinocerebellar ataxia (SCA), establishing this repeat expansion as the underlying mutation in this disease later classified as SCA17.
      </p>
     </div>
    </section>
    <section class="scrollspy" spy-title="Epidemiology">
      <div class="epi-section">
        <h2> Epidemiology</h2>
        <p>
          According to <a href="https://www.ncbi.nlm.nih.gov/books/NBK1438/">Gene Reviews</a>, fewer than 100 families with SCA17 have been reported. The prevalence of SCA17 in the Japanese population is estimated at 0.47:1,000,000.
        </p>
        <p>
          SCA17 accounts for approximately 0.3% of autosomal dominant SCA <span class="refbig"><a href="#ref-two">[2]</a></span><span class="reflittle"><a href="#ref-two-little">[2]</a></span>. The minimum prevalence of SCA17 in northeast England is 0.16:100,000
          <span class="refbig"><a href="#ref-three">[3]</a></span><span class="reflittle"><a href="#ref-three-little">[3]</a></span>. In a study of the Yugoslav population, none of the 115 individuals with autosomal dominant cerebellar ataxia or simplex cases of adult-onset ataxia had SCA17
          <span class="refbig"><a href="#ref-four">[4]</a></span><span class="reflittle"><a href="#ref-four-little">[4]</a></span>. The prevalence of SCA17 may be underestimated because some individuals with SCA17 have a phenotype like that of Huntington disease.
        </p>
        <p>
          SCA17 currently has very few reported cases therefore there is still no comparable data on SCA17 epidemiology across the world (<a href="#epi-img">Figure 1</a>).
        </p>
        <input type="checkbox" id="zoomCheck">
        <label for="zoomCheck">
          <img id="epi-img" src="../../Images/original images/SCA17/SCA17_epi.png">
        </label>
      <figcaption> <strong>Figure 1:</strong> : Countries with reported cases of SCA17. Created with <a href="https://www.mapchart.net/">MapChart</a>.</figcaption>
        <a class="download-image" href="../../Images/original images/SCA17/SCA17_epi.png" download> [Fullsize image] </a>
      </div>
    </section>
    <section class="scrollspy" spy-title="Causative gene">
        <div class="gene-section">
          <h2> Causative gene</h2>
          <p>
            TBP is the gene affected in this SCA. It has a size of 18.5kb with a plus strand orientation and 8 exons, from which 7 are coding exons. According to many authors, the pathological CAG repeats are found in exon 3 <span class="refbig"><a href="#ref-five">[5]</a></span><span class="reflittle"><a href="#ref-five-little">[5]</a></span> (<a href="#gene-image1">Figure 2</a>).
          </p>
          <p>
            Previous studies have shown that the wild-type alleles of TBP have 25 to 42 CAG/CAA repeats, whereas most SCA17 alleles range between 45 and 66 CAG/CAA repeats.
          </p>
          <p>
            It is located on chromosome 6 (cytogenic band: 6q27, <a href="#gene-image2">Figure 3</a>).
          </p>
          <div class="image-one">
            <img id="gene-image1" src="../../Images/original images/SCA17/TBP.png" title="TBP gene">
            <figcaption> <strong>Figure 2:</strong> TBP gene with ranges of the CAG repeats necessary for disease and range in healthy individuals along with information about the total coding exons, chromosome location and size in DNA bases. Created with <a href="https://biorender.com/"> BioRender.com</a></figcaption>
            <a class="download-image" target="_blank" href="../../Images/original images/SCA17/TBP.png" download> [Fullsize image] </a>
          </div>
          <div class="image-two">
            <img id="gene-image2" src="../../Images/original images/SCA17/chromosome.png" title="TBP gene chromosomal location">
            <figcaption> <strong>Figure 3:</strong> TBP gene chromossomal band localization. Created with <a href="https://biorender.com/"> BioRender.com</a></figcaption>
            <a class="download-image" target="_blank" href="../../Images/original images/SCA17/chromosome.png" download> [Fullsize image] </a>
          </div>
        </div>
    </section>
    <section class="scrollspy" spy-title="Codified protein">
      <div class="protein-section">
        <h2> Codified protein: structure, domains, functions and intracellular localization</h2>
        <h3>Structure and domains</h3>
        <p>
          TBP gene codes for the TATA-Box binding protein that has a length of 339 aa and a molecular mass of 37698 Da (isoform a) (<a href="#protein-image">Figure 4</a>). Widely expressed, with levels highest in the testis and ovary. TBP is a general transcription factor that functions at the core of the DNA-binding multiprotein factor TFIID.
        </p>
        <p>
           A TBP representation is shown in <a href="#protein-image">Figure 4</a> along with <a href="#table">Table 1</a> with information on each important domain/repeats (information from <a href="https://www.uniprot.org/">Uniprot.org</a>).
        </p>
        <div class="non-interactive">
          <img id="protein-image" src="../../Images/original images/SCA17/protein.png" title="TBP structure">
          <figcaption> <strong>Figure 4: </strong> TATA box binding protein with representation of its important domains along with range of glutamines for disease development. Created with <a href="https://biorender.com/"> BioRender.com</a></figcaption>
          <a class="download-image" target="_blank" href="../../Images/original images/SCA17/protein.png" download> [Fullsize image] </a>
        </div>
        <div class="table">
        <table style="width:100%" id="table">
          <caption>Table 1. TBP repeats</caption>
          <tr>
            <th>Description</th>
            <th>Position</th>
            <th>Length</th>
          </tr>
          <tr>
            <td>Repeat 1</td>
            <td>165-241</td>
            <td>77</td>
          </tr>
          <tr>
            <td>Repeat 2</td>
            <td>255-332</td>
            <td>78</td>
          </tr>
        </table>
        <div class="caption-under"> <strong>Table Caption:</strong> TBP repeats with respective positions within the protein structure and lengths.</div>
      </div>
        <h3>Protein functions and biological role</h3>
        <p>
          The TATA-binding protein (TBP) is a general transcription factor that binds specifically to a DNA sequence called the TATA box. This DNA sequence is found about 30 base pairs upstream of the transcription start site in some eukaryotic gene promoters.
        </p>
        <p>
          TBP is a general transcription factor that functions at the core of the DNA-binding multiprotein factor TFIID. Binding of TFIID to the TATA box is the initial transcriptional step of the pre-initiation complex (PIC), playing important roles in the activation of eukaryotic genes transcribed by RNA polymerase II <span class="refbig"><a href="#ref-six">[6]</a></span><span class="reflittle"><a href="#ref-six-little">[6]</a></span>,
          <span class="refbig"><a href="#ref-seven">[7]</a></span><span class="reflittle"><a href="#ref-seven-little">[7]</a></span>:
        </p>
        <ul>
          <li>RNA polymerase II general transcription initiation factor activity <span class="refbig"><a href="#ref-eight">[8]</a></span><span class="reflittle"><a href="#ref-eight-little">[8]</a></span>.</li>
          <li>RNA polymerase II general transcription initiation factor binding <span class="refbig"><a href="#ref-eight">[8]</a></span><span class="reflittle"><a href="#ref-eight-little">[8]</a></span>,
            <span class="refbig"><a href="#ref-nine">[9]</a></span><span class="reflittle"><a href="#ref-nine-little">[9]</a></span>.</li>
          <li>RNA polymerase II core promoter sequence-specific DNA binding <span class="refbig"><a href="#ref-eight">[8]</a></span><span class="reflittle"><a href="#ref-eight-little">[8]</a></span>.</li>
        </ul>
        <p>
          <br>
          TBP also plays important roles in transcription mediated by RNA polymerase I and III:
        </p>
        <ul>
          <li>It is a component of a BRF2-containing transcription factor complex that regulates transcription mediated by RNA polymerase III - RNA polymerase III general transcription initiation factor activity <span class="refbig"><a href="#ref-ten">[10]</a></span><span class="reflittle"><a href="#ref-ten-little">[10]</a></span>.</li>
          <li>Component of the transcription factor SL1/TIF-IB complex, which is involved in the assembly of the PIC (pre-initiation complex) during RNA polymerase I-dependent transcription <span class="refbig"><a href="#ref-eleven">[11]</a></span><span class="reflittle"><a href="#ref-eleven-little">[11]</a></span>.</li>
        </ul>
        <p>
          <br>
          In sum, TBP is involved in the following processes:
        </p>
        <ul>
          <li>DNA-templated transcription, initiation</li>
          <li>Positive regulation of transcription, DNA-templated</li>
          <li>RNA polymerase II preinitiation complex assembly</li>
          <li>Transcription by RNA polymerase I</li>
          <li>Transcription by RNA polymerase II</li>
          <li>Transcription by RNA polymerase III</li>
          <li>Transcription initiation from RNA polymerase II promoter</li>
        </ul>
        <h3> Protein intracellular localization</h3>
        <p>
          TATA-Box binding protein is found in the cell nucleus where it engages with the DNA and performs its function of transcription initiation by mainly RNA-polymerase II <span class="refbig"><a href="#ref-twelve">[12]</a></span><span class="reflittle"><a href="#ref-twelve-little">[12]</a></span>.
        </p>
        <div class="interactive-image" id="my-interactive-image">
          <img src="../../Images/cell-scheme.jpg" />
        </div>
        <div class="int-caption"> <strong>Figure 5:</strong> TATA Box binding protein localization.<br>(Refresh this element if changed resolutions &nbsp<a href="javascript:void(0)" onclick="window.location.reload();"><i class="fa-solid fa-arrows-rotate"></i></a>&nbsp)</div>
        <!-- <div class="iactiveImg" data-ii="38987"></div>
        <script src="https://interactive-img.com/js/include.js"></script> -->
        <!-- https://codepen.io/jpchateau/pen/vYOvGeE <-- TRY THIS -->
      </div>
    </section>
    <section class="scrollspy" spy-title="Pathophysiology">
      <div class="patho-section">
        <h2> Pathophysiology</h2>
        <p>
          Expression of mutant TBP appears to lead to two important consequences. One is the formation of nuclear aggregates or inclusions (NIIs); the other is the reduction of endogenous normal TBP <span class="refbig"><a href="#ref-thirteen">[13]</a></span><span class="reflittle"><a href="#ref-thirteen-little">[13]</a></span>,
          <span class="refbig"><a href="#ref-fourteen">[14]</a></span><span class="reflittle"><a href="#ref-fourteen-little">[14]</a></span>.
        </p>
        <p>
          Overexpression of full-length-mutant TBP and truncated-mutant TBP lacking the DNA-binding domains (DBDs) was found to cause formation of inclusions, suggesting that insoluble aggregates are disease factors and that the neurotoxicity of mutant TBP is independent of DNA binding <span class="refbig"><a href="#ref-fifteen">[15]</a></span><span class="reflittle"><a href="#ref-fifteen-little">[15]</a></span>.
        </p>
        <p>
          On first analysis, the pathogenesis of SCA17 seems similar to that of other polyQ diseases. On the other hand, whether expanded polyQ tracts affect the function of TBP has yet to be comprehensively addressed. As mentioned before, TBP is a general transcription factor essential for formation of the transcription preinitiation complex and transcription of RNA polymerases I, II and III (Pol I, II and III). With abnormal TBP, cellular functions would be compromised and eventually lead to cell death. Inactivation of TBP in mice causes downregulation of Pol I and Pol III transcription, growth arrest and cell death <span class="refbig"><a href="#ref-sixteen">[16]</a></span><span class="reflittle"><a href="#ref-sixteen-little">[16]</a></span>.
        </p>
        <p>
          In mouse models, polyQ expanded TBP has been shown to bind less to DNA <span class="refbig"><a href="#ref-seventeen">[17]</a></span><span class="reflittle"><a href="#ref-seventeen-little">[17]</a></span>, and that polyQ-expanded TBP fragments, which are incapable of binding DNA, formed nuclear inclusions and caused severe neurological phenotypes
          <span class="refbig"><a href="#ref-seventeen">[17]</a></span><span class="reflittle"><a href="#ref-seventeen-little">[17]</a></span>. Modified SCA17 mice expressing mutant TBP fragments lacking an intact C-terminal DNA-binding domain showed more severe neurological symptoms
          <span class="refbig"><a href="#ref-fourteen">[14]</a></span><span class="reflittle"><a href="#ref-fourteen-little">[14]</a></span>. Truncated mutant TBP forms aggregates more easily than full-length mutant TBP in transfected cells
          <span class="refbig"><a href="#ref-fourteen">[14]</a></span><span class="reflittle"><a href="#ref-fourteen-little">[14]</a></span>. This phenomenon suggests that mutant TBP can induce neurotoxicity without binding to DNA and that truncated TBP is more toxic than full-length TBP
          <span class="refbig"><a href="#ref-seventeen">[17]</a></span><span class="reflittle"><a href="#ref-seventeen-little">[17]</a></span>.
        </p>
        <img id="patho-img" src="../../Images/original images/SCA17/SCA17.png" title="SCA17 pathogenic mechanisms">
        <div class="caption-patho"> <strong>Figure 6:</strong> SCA17 pathogenesis. Mutated TBPs do not have functioning dna binding domains this leads to increased concentrations of non-functioning TBP inside the cell nucleus and formation of aggregates of these mutated TBPs. With the appearence of several aggregates and increased concentration of mutated TBP the cell has several problems performing transcription functions which eventually will end in cellular death.</div>
        <a class="download-image" target="_blank" href="../../Images/original images/SCA17/SCA17.png" download> [Fullsize image] </a>
      </div>
    </section>
    <section class="scrollspy" spy-title="Clinical manifestations">
      <div class="clinical-section">
        <h2> Clinical manifestations: neuropathology, other signs and symptoms</h2>
        <h3>Neuropathology</h3>
        <p>
          SCA17 patients usually show TBP and NIIs accumulated in the Purkinje cell layer, cerebral cortex, neostriatum and hippocampal CA1, and subiculum <span class="refbig"><a href="#ref-eighteen">[18]</a></span><span class="reflittle"><a href="#ref-eighteen-little">[18]</a></span>. The brain shows atrophy of the striatum (more apparent in the caudate nucleus) and cerebellum, mild atrophy in the caudate nucleus and putamen. Histologically, neuronal loss along with some eventual gliosis is observed in the striatum, Purkinje cell layer and cerebral cortex (deep layers)
          <span class="refbig"><a href="#ref-nineteen">[19]</a></span><span class="reflittle"><a href="#ref-nineteen-little">[19]</a></span>. Loss of cerebral cortical neurons is seen in some individuals
          <span class="refbig"><a href="#ref-one">[1]</a></span><span class="reflittle"><a href="#ref-one-little">[1]</a></span>. Mild neuronal may also be found in the cornu ammonis region 1 (CA1) of Ammon’s horn, subiculum, parahippocampal gyrus, brainstem reticular formation, and inferior olivary nucleus
          <span class="refbig"><a href="#ref-nineteen">[19]</a></span><span class="reflittle"><a href="#ref-nineteen-little">[19]</a></span>.
        </p>
        <p>
          According to some authors, the overall size of the brain may be reduced with brainstem and cerebellum smaller than normal <span class="refbig"><a href="#ref-eighteen">[18]</a></span><span class="reflittle"><a href="#ref-eighteen-little">[18]</a></span>. Substantia nigra and white matter may sometimes be atrophied and with reduced thickness, respectively
          <span class="refbig"><a href="#ref-eighteen">[18]</a></span><span class="reflittle"><a href="#ref-eighteen-little">[18]</a></span>.
        </p>
        <h3> Signs and symptoms</h3>
        <div class="list-flex">
          <div class="column-one">
            <div class="column-one-title">
              <strong>Initial findings</strong>
            </div>
          <ul>
            <li>Ataxia</li>
            <li>Psychiatric abnormalities </li>
            <li>Cognitive dysfunction</li>
            <li>Memory disturbance</li>
          </ul>
          </div>
          <div class="column-two">
            <div class="column-two-title">
              <strong>As disease progresses</strong>
            </div>
          <ul>
            <li>Involuntary movement</li>
            <li>Parkinsonism</li>
            <li>Dementia</li>
            <li>Gait instability</li>
            <li>Slurred speech</li>
          </ul>
          </div>
      </div>
      <p>
        During the disease course, most of the patients (>90%) developed ataxia, which is manifested as gait instability, and slurred speech. Cognitive dysfunction and memory disturbance have also been recognized as an initial symptom <span class="refbig"><a href="#ref-twenty">[20]</a></span><span class="reflittle"><a href="#ref-twenty-little">[20]</a></span>; dementia is the second most common symptom (73%) during the disease course. In childhood, mental deterioration may occur instead of dementia. Psychiatric symptoms, such as aggression, paranoia, euphoria and depression are observed frequently
        <span class="refbig"><a href="#ref-twenty-one">[21]</a></span><span class="reflittle"><a href="#ref-twenty-one-little">[21]</a></span> -
        <span class="refbig"><a href="#ref-twenty-three">[23]</a></span><span class="reflittle"><a href="#ref-twenty-three-little">[23]</a></span>.
      </p>
      </div>
    </section>
    <section class="scrollspy" spy-title="References" id="references">
      <div class="reference-section">
        <h2> References </h2>
        <ol>
          <li><a id="ref-one-little" class="articlebottom">Y. Toyoshima and H. Takahashi, “Spinocerebellar Ataxia Type 17 (SCA17),” Adv. Exp. Med. Biol., vol. 1049, pp. 219–231, 2018.</a><br><a href="https://pubmed.ncbi.nlm.nih.gov/29427105/" class="links">[PUBMED]</a><a href="https://link.springer.com/chapter/10.1007/978-3-319-71779-1_10" class="links">[Springer]</a></li>
          <li><a id="ref-two-little" class="articlebottom">H. Maruyama, Y. Izumi, H. Morino, M. Oda, S. N. Hiromasa Toji, and H. Kawakami, “Difference in disease-free survival curve and regional distribution according to subtype of spinocerebellar ataxia: a study of 1,286 Japanese patients,” Am. J. Med. Genet., vol. 114, no. 5, pp. 578–583, Jul. 2002.</a><br><a href="https://onlinelibrary.wiley.com/doi/10.1002/ajmg.10514" class="links">[Wiley Online Library]</a></li>
          <li><a id="ref-three-little" class="articlebottom">K. Craig, S. M. Keers, T. J. Walls, A. Curtis, and P. F. Chinnery, “Minimum prevalence of spinocerebellar ataxia 17 in the north east of England,” J. Neurol. Sci., vol. 239, no. 1, pp. 105–109, Dec. 2005.</a><br><a href="https://www.sciencedirect.com/science/article/abs/pii/S0022510X05003035" class="links">[ScienceDirect]</a><a href="https://www.jns-journal.com/article/S0022-510X(05)00303-5/fulltext" class="links">[JNS]</a></li>
          <li><a id="ref-four-little" class="articlebottom">A. Alendar et al., “Spinocerebellar ataxia type 17 in the Yugoslav population,” Acta Neurol. Scand., vol. 109, no. 3, pp. 185–187, 2004.</a><br><a href="https://pubmed.ncbi.nlm.nih.gov/14763955/" class="links">[PUBMED]</a><a href="https://onlinelibrary.wiley.com/doi/abs/10.1034/j.1600-0404.2003.00196.x" class="links">[Wiley Online Library]</a></li>
          <li><a id="ref-five-little" class="articlebottom">C. S. McIntosh, D. Li, S. D. Wilton, and M. T. Aung-Htut, “Polyglutamine Ataxias: Our Current Molecular Understanding and What the Future Holds for Antisense Therapies,” Biomedicines, vol. 9, no. 11, Nov. 2021.</a><br><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8615177/" class="links">[PUBMED Central - Full Text]</a><a href="https://www.mdpi.com/2227-9059/9/11/1499" class="links">[MDPI - Full Text]</a></li>
          <li><a id="ref-six-little" class="articlebottom">A. Hoffmann et al., “Highly conserved core domain and unique N terminus with presumptive regulatory motifs in a human TATA factor (TFIID),” Nature, vol. 346, no. 6282, pp. 387–390, 1990.</a><br><a href="https://pubmed.ncbi.nlm.nih.gov/2374612/" class="links">[PUBMED]</a><a href="https://www.nature.com/articles/346387a0" class="links">[Nature]</a></li>
          <li><a id="ref-seven-little" class="articlebottom">M. G. Peterson, N. Tanese, B. Franklin Pugh, and R. Tjian, “Functional domains and upstream activation properties of cloned human TATA binding protein,” Science, vol. 248, no. 4963, pp. 1625–1630, 1990.</a><br><a href="https://pubmed.ncbi.nlm.nih.gov/2363050/" class="links">[PUBMED]</a><a href="https://www.science.org/doi/10.1126/science.2363050" class="links">[Science]</a></li>
          <li><a id="ref-eight-little" class="articlebottom">K. Gupta et al., “Architecture of TAF11/TAF13/TBP complex suggests novel regulation properties of general transcription factor TFIID,” Elife, vol. 6, Nov. 2017.</a><br><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5690282/" class="links">[PUBMED Central - Full Text]</a><a href="https://elifesciences.org/articles/30395" class="links">[eLife - Full Text]</a></li>
          <li><a id="ref-nine-little" class="articlebottom">A. Goppelt, G. Stelzer, F. Lottspeich, and M. Meisterernst, “A mechanism for repression of class II gene transcription through specific binding of NC2 to TBP-promoter complexes via heterodimeric histone fold domains.,” EMBO J., vol. 15, no. 12, p. 3105, 1996.</a><br><a href="https://www.embopress.org/doi/abs/10.1002/j.1460-2075.1996.tb00673.x" class="links">[EMBOpress]</a></li>
          <li><a id="ref-ten-little" class="articlebottom">J. Gouge et al., “Redox Signaling by the RNA Polymerase III TFIIB-Related Factor Brf2,” Cell, vol. 163, no. 6, pp. 1375–1387, Dec. 2015.</a><br><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4671959/" class="links">[PUBMED Central - Full Text]</a><a href="https://www.cell.com/cell/fulltext/S0092-8674(15)01485-3" class="links">[Cell - Full Text]</a></li>
          <li><a id="ref-eleven-little" class="articlebottom">J. K. Friedrich, K. I. Panov, P. Cabart, J. Russell, and J. C. B. M. Zomerdijk, “TBP-TAF complex SL1 directs RNA polymerase I pre-initiation complex formation and stabilizes upstream binding factor at the rDNA promoter,” J. Biol. Chem., vol. 280, no. 33, pp. 29551–29558, Aug. 2005.</a><br><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3858828/" class="links">[PUBMED Central - Full Text]</a><a href="https://www.jbc.org/article/S0021-9258(20)56380-1/fulltext" class="links">[JBC - Full Text]</a></li>
          <li><a id="ref-twelve-little" class="articlebottom">R. K. Louder, Y. He, J. R. López-Blanco, J. Fang, P. Chacón, and E. Nogales, “Structure of promoter-bound TFIID and model of human pre-initiation complex assembly,” Nature, vol. 531, no. 7596, pp. 604–609, Mar. 2016.</a><br><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4856295/" class="links">[PUBMED Central - Full Text]</a></li>
          <li><a id="ref-thirteen-little" class="articlebottom">S. Huang, J. J. Ling, S. Yang, X. J. Li, and S. Li, “Neuronal expression of TATA box-binding protein containing expanded polyglutamine in knock-in mice reduces chaperone protein response by impairing the function of nuclear factor-Y transcription factor,” Brain, vol. 134, no. Pt 7, pp. 1943–1958, Jul. 2011.</a><br><a href="https://academic.oup.com/brain/article/134/7/1943/296239" class="links">[Oxford Academic - Full Text]</a><a href="https://www.researchgate.net/publication/51250035_Neuronal_expression_of_TATA_box-binding_protein_containing_expanded_polyglutamine_in_knock-in_mice_reduces_chaperone_protein_response_by_impairing_the_function_of_nuclear_factor-Y_transcription_factor" class="links">[ResearchGate - PDF]</a></li>
          <li><a id="ref-fourteen-little" class="articlebottom">M. J. Friedman et al., “Polyglutamine domain modulates the TBP-TFIIB interaction: implications for its normal function and neurodegeneration,” Nat. Neurosci., vol. 10, no. 12, pp. 1519–1528, Dec. 2007.</a><br><a href="https://www.nature.com/articles/nn2011" class="links">[Nature]</a></li>
          <li><a id="ref-fifteen-little" class="articlebottom">T. C. Hsu et al., “Deactivation of TBP contributes to SCA17 pathogenesis,” Hum. Mol. Genet., vol. 23, no. 25, pp. 6878–6893, Dec. 2014.</a><br><a href="https://academic.oup.com/hmg/article/23/25/6878/572126" class="links">[Oxford Academic - Full Text]</a></li>
          <li><a id="ref-sixteen-little" class="articlebottom">I. Martianov, S. Viville, and I. Davidson, “RNA polymerase II transcription in murine cells lacking the TATA binding protein,” Science, vol. 298, no. 5595, pp. 1036–1039, Nov. 2002.</a><br><a href="https://pubmed.ncbi.nlm.nih.gov/12411709/" class="links">[PUBMED]</a><a href="https://www.science.org/doi/10.1126/science.1076327" class="links">[Science]</a></li>
          <li><a id="ref-seventeen-little" class="articlebottom">M. J. Friedman, C. E. Wang, X. J. Li, and S. Li, “Polyglutamine expansion reduces the association of TATA-binding protein with DNA and induces DNA binding-independent neurotoxicity,” J. Biol. Chem., vol. 283, no. 13, pp. 8283–8290, Mar. 2008.</a><br><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2276379/" class="links">[PUBMED Central - Full Text]</a><a href="https://www.jbc.org/article/S0021-9258(20)52784-1/fulltext" class="links">[JBC - Full Text]</a></li>
          <li><a id="ref-eighteen-little" class="articlebottom">A. Rolfs et al., “Clinical features and neuropathology of autosomal dominant spinocerebellar ataxia (SCA17),” Ann. Neurol., vol. 54, no. 3, pp. 367–375, Sep. 2003.</a><br><a href="https://pubmed.ncbi.nlm.nih.gov/12953269/" class="links">[PUBMED]</a><a href="https://onlinelibrary.wiley.com/doi/10.1002/ana.10676" class="links">[Wiley Online Library]</a></li>
          <li><a id="ref-nineteen-little" class="articlebottom">C. Nóbrega. C. Matos, L. Pereira de Almeida, “Polyglutamine Disorders,” J. Neurochem., vol. 1049, no. September, pp. 219–231, 2018.</a><br><a href="https://link.springer.com/book/10.1007/978-3-319-71779-1" class="links"></a></li></a></li>
          <li><a id="ref-twenty-little" class="articlebottom">T. T. Nielsen et al., “Severe and rapidly progressing cognitive phenotype in a SCA17-family with only marginally expanded CAG/CAA repeats in the TATA-box binding protein gene: A case report,” BMC Neurol., vol. 12, no. 1, pp. 1–5, Aug. 2012.</a><br><a href="https://bmcneurol.biomedcentral.com/articles/10.1186/1471-2377-12-73" class="links">[BMC - Full Text]</a><a href="https://www.researchgate.net/publication/230664987_Severe_and_rapidly_progressing_cognitive_phenotype_in_a_SCA17-family_with_only_marginally_expanded_CAGCAA_repeats_in_the_TATA-box_binding_protein_gene_A_case_report" class="links">[ResearchGate - PDF]</a></li>
          <li><a id="ref-twenty-one-little" class="articlebottom">H. Fujigasaki et al., “CAG repeat expansion in the TATA box-binding protein gene causes autosomal dominant cerebellar ataxia,” Brain, vol. 124, no. Pt 10, pp. 1939–1947, 2001.</a><br><a href="https://academic.oup.com/brain/article/124/10/1939/333481" class="links">[Oxford Academic - Full Text]</a></li>
          <li><a id="ref-twenty-two-little" class="articlebottom">S. A. Schneider et al., “Phenotypic homogeneity of the Huntington disease-like presentation in a SCA17 family,” Neurology, vol. 67, no. 9, pp. 1701–1703, Nov. 2006.</a><br><a href="https://pubmed.ncbi.nlm.nih.gov/17101913/" class="links">[PUBMED]</a><a href="https://pubmed.ncbi.nlm.nih.gov/17101913/" class="links">[PUBMED]</a><a href="https://n.neurology.org/content/67/9/1701.long" class="links">[Neurology]</a></li>
          <li><a id="ref-twenty-three-little" class="articlebottom">I. S. Lin, R. M. Wu, G. J. Lee-Chen, D. E. Shan, and K. Gwinn-Hardy, “The SCA17 phenotype can include features of MSA-C, PSP and cognitive impairment,” Parkinsonism Relat. Disord., vol. 13, no. 4, pp. 246–249, May 2007.</a><br><a href="https://www.sciencedirect.com/science/article/abs/pii/S1353802006000903" class="links">[ScienceDirect]</a><a href="https://www.prd-journal.com/article/S1353-8020(06)00090-3/fulltext" class="links">[PRD]</a></li>
        </ol>
      </div>
    </section>
    </div>
    <div class="aside-bar-right" id="bar-right">
      <div class="ref-side-bar">
        <h3><i class="fa-solid fa-link"></i> References</h3>
        <ul>
          <li><a href="" id="ref-one" class="articlefocus">1. &nbspY. Toyoshima and H. Takahashi, “Spinocerebellar Ataxia Type 17 (SCA17),” Adv. Exp. Med. Biol., vol. 1049, pp. 219–231, 2018.</a><br><a href="https://pubmed.ncbi.nlm.nih.gov/29427105/" class="links">[PUBMED]</a><a href="https://link.springer.com/chapter/10.1007/978-3-319-71779-1_10" class="links">[Springer]</a></li>
          <li><a href="" id="ref-two" class="articlefocus">2. &nbspH. Maruyama, Y. Izumi, H. Morino, M. Oda, S. N. Hiromasa Toji, and H. Kawakami, “Difference in disease-free survival curve and regional distribution according to subtype of spinocerebellar ataxia: a study of 1,286 Japanese patients,” Am. J. Med. Genet., vol. 114, no. 5, pp. 578–583, Jul. 2002.</a><br><a href="https://onlinelibrary.wiley.com/doi/10.1002/ajmg.10514" class="links">[Wiley Online Library]</a></li>
          <li><a href="" id="ref-three" class="articlefocus">3. &nbspK. Craig, S. M. Keers, T. J. Walls, A. Curtis, and P. F. Chinnery, “Minimum prevalence of spinocerebellar ataxia 17 in the north east of England,” J. Neurol. Sci., vol. 239, no. 1, pp. 105–109, Dec. 2005.</a><br><a href="https://www.sciencedirect.com/science/article/abs/pii/S0022510X05003035" class="links">[ScienceDirect]</a><a href="https://www.jns-journal.com/article/S0022-510X(05)00303-5/fulltext" class="links">[JNS]</a></li>
          <li><a href="" id="ref-four" class="articlefocus">4. &nbspA. Alendar et al., “Spinocerebellar ataxia type 17 in the Yugoslav population,” Acta Neurol. Scand., vol. 109, no. 3, pp. 185–187, 2004.</a><br><a href="https://pubmed.ncbi.nlm.nih.gov/14763955/" class="links">[PUBMED]</a><a href="https://onlinelibrary.wiley.com/doi/abs/10.1034/j.1600-0404.2003.00196.x" class="links">[Wiley Online Library]</a></li>
          <li><a href="" id="ref-five" class="articlefocus">5. &nbspC. S. McIntosh, D. Li, S. D. Wilton, and M. T. Aung-Htut, “Polyglutamine Ataxias: Our Current Molecular Understanding and What the Future Holds for Antisense Therapies,” Biomedicines, vol. 9, no. 11, Nov. 2021.</a><br><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8615177/" class="links">[PUBMED Central - Full Text]</a><a href="https://www.mdpi.com/2227-9059/9/11/1499" class="links">[MDPI - Full Text]</a></li>
          <li><a href="" id="ref-six" class="articlefocus">6. &nbspA. Hoffmann et al., “Highly conserved core domain and unique N terminus with presumptive regulatory motifs in a human TATA factor (TFIID),” Nature, vol. 346, no. 6282, pp. 387–390, 1990.</a><br><a href="https://pubmed.ncbi.nlm.nih.gov/2374612/" class="links">[PUBMED]</a><a href="https://www.nature.com/articles/346387a0" class="links">[Nature]</a></li>
          <li><a href="" id="ref-seven" class="articlefocus">7. &nbspM. G. Peterson, N. Tanese, B. Franklin Pugh, and R. Tjian, “Functional domains and upstream activation properties of cloned human TATA binding protein,” Science, vol. 248, no. 4963, pp. 1625–1630, 1990.</a><br><a href="https://pubmed.ncbi.nlm.nih.gov/2363050/" class="links">[PUBMED]</a><a href="https://www.science.org/doi/10.1126/science.2363050" class="links">[Science]</a></li>
          <li><a href="" id="ref-eight" class="articlefocus">8. &nbspK. Gupta et al., “Architecture of TAF11/TAF13/TBP complex suggests novel regulation properties of general transcription factor TFIID,” Elife, vol. 6, Nov. 2017.</a><br><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5690282/" class="links">[PUBMED Central - Full Text]</a><a href="https://elifesciences.org/articles/30395" class="links">[eLife - Full Text]</a></li>
          <li><a href="" id="ref-nine" class="articlefocus">9. &nbspA. Goppelt, G. Stelzer, F. Lottspeich, and M. Meisterernst, “A mechanism for repression of class II gene transcription through specific binding of NC2 to TBP-promoter complexes via heterodimeric histone fold domains.,” EMBO J., vol. 15, no. 12, p. 3105, 1996.</a><br><a href="https://www.embopress.org/doi/abs/10.1002/j.1460-2075.1996.tb00673.x" class="links">[EMBOpress]</a></li>
          <li><a href="" id="ref-ten" class="articlefocus">10. &nbspJ. Gouge et al., “Redox Signaling by the RNA Polymerase III TFIIB-Related Factor Brf2,” Cell, vol. 163, no. 6, pp. 1375–1387, Dec. 2015.</a><br><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4671959/" class="links">[PUBMED Central - Full Text]</a><a href="https://www.cell.com/cell/fulltext/S0092-8674(15)01485-3" class="links">[Cell - Full Text]</a></li>
          <li><a href="" id="ref-eleven" class="articlefocus">11. &nbspJ. K. Friedrich, K. I. Panov, P. Cabart, J. Russell, and J. C. B. M. Zomerdijk, “TBP-TAF complex SL1 directs RNA polymerase I pre-initiation complex formation and stabilizes upstream binding factor at the rDNA promoter,” J. Biol. Chem., vol. 280, no. 33, pp. 29551–29558, Aug. 2005.</a><br><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3858828/" class="links">[PUBMED Central - Full Text]</a><a href="https://www.jbc.org/article/S0021-9258(20)56380-1/fulltext" class="links">[JBC - Full Text]</a></li>
          <li><a href="" id="ref-twelve" class="articlefocus">12. &nbspR. K. Louder, Y. He, J. R. López-Blanco, J. Fang, P. Chacón, and E. Nogales, “Structure of promoter-bound TFIID and model of human pre-initiation complex assembly,” Nature, vol. 531, no. 7596, pp. 604–609, Mar. 2016.</a><br><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4856295/" class="links">[PUBMED Central - Full Text]</a></li>
          <li><a href="" id="ref-thirteen" class="articlefocus">13. &nbspS. Huang, J. J. Ling, S. Yang, X. J. Li, and S. Li, “Neuronal expression of TATA box-binding protein containing expanded polyglutamine in knock-in mice reduces chaperone protein response by impairing the function of nuclear factor-Y transcription factor,” Brain, vol. 134, no. Pt 7, pp. 1943–1958, Jul. 2011.</a><br><a href="https://academic.oup.com/brain/article/134/7/1943/296239" class="links">[Oxford Academic - Full Text]</a><a href="https://www.researchgate.net/publication/51250035_Neuronal_expression_of_TATA_box-binding_protein_containing_expanded_polyglutamine_in_knock-in_mice_reduces_chaperone_protein_response_by_impairing_the_function_of_nuclear_factor-Y_transcription_factor" class="links">[ResearchGate - PDF]</a></li>
          <li><a href="" id="ref-fourteen" class="articlefocus">14. &nbspM. J. Friedman et al., “Polyglutamine domain modulates the TBP-TFIIB interaction: implications for its normal function and neurodegeneration,” Nat. Neurosci., vol. 10, no. 12, pp. 1519–1528, Dec. 2007.</a><br><a href="https://www.nature.com/articles/nn2011" class="links">[Nature]</a></li>
          <li><a href="" id="ref-fifteen" class="articlefocus">15. &nbspT. C. Hsu et al., “Deactivation of TBP contributes to SCA17 pathogenesis,” Hum. Mol. Genet., vol. 23, no. 25, pp. 6878–6893, Dec. 2014.</a><br><a href="https://academic.oup.com/hmg/article/23/25/6878/572126" class="links">[Oxford Academic - Full Text]</a></li>
          <li><a href="" id="ref-sixteen" class="articlefocus">16. &nbspI. Martianov, S. Viville, and I. Davidson, “RNA polymerase II transcription in murine cells lacking the TATA binding protein,” Science, vol. 298, no. 5595, pp. 1036–1039, Nov. 2002.</a><br><a href="https://pubmed.ncbi.nlm.nih.gov/12411709/" class="links">[PUBMED]</a><a href="https://www.science.org/doi/10.1126/science.1076327" class="links">[Science]</a></li>
          <li><a href="" id="ref-seventeen" class="articlefocus">17. &nbspM. J. Friedman, C. E. Wang, X. J. Li, and S. Li, “Polyglutamine expansion reduces the association of TATA-binding protein with DNA and induces DNA binding-independent neurotoxicity,” J. Biol. Chem., vol. 283, no. 13, pp. 8283–8290, Mar. 2008.</a><br><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2276379/" class="links">[PUBMED Central - Full Text]</a><a href="https://www.jbc.org/article/S0021-9258(20)52784-1/fulltext" class="links">[JBC - Full Text]</a></li>
          <li><a href="" id="ref-eighteen" class="articlefocus">18. &nbspA. Rolfs et al., “Clinical features and neuropathology of autosomal dominant spinocerebellar ataxia (SCA17),” Ann. Neurol., vol. 54, no. 3, pp. 367–375, Sep. 2003.</a><br><a href="https://pubmed.ncbi.nlm.nih.gov/12953269/" class="links">[PUBMED]</a><a href="https://onlinelibrary.wiley.com/doi/10.1002/ana.10676" class="links">[Wiley Online Library]</a></li>
          <li><a href="" id="ref-nineteen" class="articlefocus">19. &nbspC. Nóbrega. C. Matos, L. Pereira de Almeida, “Polyglutamine Disorders,” J. Neurochem., vol. 1049, no. September, pp. 219–231, 2018.</a><br><a href="https://link.springer.com/book/10.1007/978-3-319-71779-1" class="links"></a></li></a></li>
          <li><a href="" id="ref-twenty" class="articlefocus">20. &nbspT. T. Nielsen et al., “Severe and rapidly progressing cognitive phenotype in a SCA17-family with only marginally expanded CAG/CAA repeats in the TATA-box binding protein gene: A case report,” BMC Neurol., vol. 12, no. 1, pp. 1–5, Aug. 2012.</a><br><a href="https://bmcneurol.biomedcentral.com/articles/10.1186/1471-2377-12-73" class="links">[BMC - Full Text]</a><a href="https://www.researchgate.net/publication/230664987_Severe_and_rapidly_progressing_cognitive_phenotype_in_a_SCA17-family_with_only_marginally_expanded_CAGCAA_repeats_in_the_TATA-box_binding_protein_gene_A_case_report" class="links">[ResearchGate - PDF]</a></li>
          <li><a href="" id="ref-twenty-one" class="articlefocus">21. &nbspH. Fujigasaki et al., “CAG repeat expansion in the TATA box-binding protein gene causes autosomal dominant cerebellar ataxia,” Brain, vol. 124, no. Pt 10, pp. 1939–1947, 2001.</a><br><a href="https://academic.oup.com/brain/article/124/10/1939/333481" class="links">[Oxford Academic - Full Text]</a></li>
          <li><a href="" id="ref-twenty-two" class="articlefocus">22. &nbspS. A. Schneider et al., “Phenotypic homogeneity of the Huntington disease-like presentation in a SCA17 family,” Neurology, vol. 67, no. 9, pp. 1701–1703, Nov. 2006.</a><br><a href="https://pubmed.ncbi.nlm.nih.gov/17101913/" class="links">[PUBMED]</a><a href="https://pubmed.ncbi.nlm.nih.gov/17101913/" class="links">[PUBMED]</a><a href="https://n.neurology.org/content/67/9/1701.long" class="links">[Neurology]</a></li>
          <li><a href="" id="ref-twenty-three" class="articlefocus">23. &nbspI. S. Lin, R. M. Wu, G. J. Lee-Chen, D. E. Shan, and K. Gwinn-Hardy, “The SCA17 phenotype can include features of MSA-C, PSP and cognitive impairment,” Parkinsonism Relat. Disord., vol. 13, no. 4, pp. 246–249, May 2007.</a><br><a href="https://www.sciencedirect.com/science/article/abs/pii/S1353802006000903" class="links">[ScienceDirect]</a><a href="https://www.prd-journal.com/article/S1353-8020(06)00090-3/fulltext" class="links">[PRD]</a></li>
        </ul>
      </div>
    </div>
  </main>
  <footer id=footer>
    <div class="collumns">
      <div class="first-third">
        <ul>
          <li><a href="">Contact</a></li>
          <li><a href="">ABCRI</a></li>
          <li><a href="">MNGT</a></li>
          <li><a href="">News</a></li>
        </ul>
      </div>
      <div class="second-third">
        <ul>
          <li><a href="">Authors</a></li>
          <li><a href="">Sources</a></li>
          <li><a href="">UALG</a></li>
          <li><a href="">Masters</a></li>
        </ul>
      </div>
      <div class="third-third">
        <ul>
          <li><a href="">Help</a></li>
          <li><a href="">Affiliations</a></li>
          <li><a href="">Thanks for visiting!</a></li>
        </ul>
      </div>
    </div>
    <svg xmlns="http://www.w3.org/2000/svg" version="1.0" width="200.000000pt" height="200.000000pt" viewBox="0 0 200.000000 200.000000" preserveAspectRatio="xMidYMid meet">
<metadata>
Created by potrace 1.10, written by Peter Selinger 2001-2011
</metadata>
<g transform="translate(0.000000,200.000000) scale(0.100000,-0.100000)" fill="#3d85c6" stroke="none">
<path d="M1514 1622 c-11 -10 -31 -22 -44 -25 -38 -10 -45 -17 -84 -82 -40 -67 -44 -94 -20 -135 18 -29 101 -80 132 -80 10 0 23 -5 29 -11 6 -6 26 -14 43 -18 24 -4 38 -16 51 -40 10 -19 23 -39 28 -44 14 -14 61 19 61 43 0 12 10 25 23 30 36 15 78 65 89 107 20 79 20 89 -8 152 -25 55 -33 64 -83 90 -72 36 -185 42 -217 13z m76 -27 c-10 -12 -10 -19 -2 -27 9 -9 18 -4 37 16 14 15 28 25 33 23 4 -2 25 -12 47 -22 40 -18 75 -43 75 -54 0 -9 -67 -7 -76 2 -12 12 -44 8 -44 -5 0 -20 48 -38 81 -31 49 9 81 -33 63 -81 -7 -19 -36 -21 -65 -3 -17 9 -23 9 -26 0 -3 -8 -14 -11 -28 -7 -12 3 -26 1 -30 -5 -3 -6 -17 -8 -31 -5 -13 3 -24 2 -24 -4 0 -19 -33 -22 -57 -6 -35 22 -52 3 -23 -24 21 -20 21 -20 2 -26 -23 -8 -117 37 -126 60 -9 24 -7 74 3 74 5 0 11 -7 15 -15 9 -26 48 -17 77 18 21 24 28 28 29 15 0 -24 22 -23 38 2 7 11 21 20 31 20 11 0 22 4 26 9 10 17 -15 23 -68 16 -38 -6 -58 -15 -78 -37 -25 -26 -29 -27 -37 -11 -19 32 20 83 64 83 8 0 23 9 34 20 11 11 32 20 46 20 23 0 25 -2 14 -15z m179 -224 l34 -1 -23 -25 c-25 -26 -59 -32 -91 -15 -15 8 -24 6 -41 -10 -13 -11 -35 -20 -54 -20 -60 0 -53 30 11 50 22 7 46 15 53 19 8 3 28 5 45 5 18 -1 47 -2 66 -3z m-34 -81 c-3 -5 -12 -10 -20 -10 -8 0 -17 5 -20 10 -4 6 5 10 20 10 15 0 24 -4 20 -10z m-61 -22 c14 -55 0 -64 -26 -19 -12 22 -13 31 -5 35 21 8 25 6 31 -16z"/>
<path d="M72 1198 c-23 -23 -14 -59 18 -71 l30 -11 0 -163 c0 -150 -1 -163 -18 -163 -37 0 -57 -51 -30 -78 15 -15 100 -15 152 -1 60 16 158 119 182 189 32 94 68 153 113 187 23 18 48 33 54 33 9 0 12 -46 12 -165 0 -91 -1 -165 -2 -165 -1 0 -13 5 -27 11 -25 12 -25 14 -28 142 l-3 130 -29 -41 c-25 -37 -28 -48 -24 -102 4 -63 -4 -78 -19 -34 -9 26 -10 26 -36 -27 l-26 -54 31 -33 c81 -83 206 -106 306 -56 81 40 129 104 177 238 20 54 73 119 117 142 l28 15 0 -166 0 -165 -22 11 c-22 10 -23 13 -20 139 3 142 -1 151 -48 88 -19 -26 -22 -40 -18 -94 2 -35 3 -64 1 -64 -1 0 -8 12 -16 26 l-14 26 -26 -53 -26 -54 32 -34 c92 -97 257 -108 353 -24 44 39 93 115 114 177 27 82 69 140 120 166 l40 20 0 -164 0 -165 -22 8 c-22 8 -23 15 -28 137 l-5 128 -29 -34 c-26 -31 -28 -39 -24 -97 4 -66 -4 -82 -19 -37 -9 26 -10 26 -36 -27 l-26 -54 32 -33 c52 -55 116 -82 191 -82 56 0 67 3 76 21 9 16 8 26 -5 45 -8 13 -22 24 -30 24 -13 0 -15 26 -15 164 0 152 1 164 19 169 31 8 43 40 25 65 -13 18 -25 22 -72 22 -131 0 -232 -90 -286 -256 -19 -57 -73 -127 -117 -149 -15 -8 -30 -15 -34 -15 -3 0 -5 74 -5 165 0 91 3 165 6 165 3 0 14 -5 25 -10 17 -10 19 -22 19 -143 l0 -132 28 28 c23 24 28 37 32 105 6 73 6 75 18 48 l13 -30 25 54 25 53 -38 39 c-54 55 -107 78 -181 78 -112 0 -206 -69 -259 -188 -13 -31 -34 -78 -45 -104 -21 -48 -51 -82 -100 -113 l-28 -17 0 166 c0 164 0 167 20 156 18 -10 20 -21 20 -143 l1 -132 36 39 c35 38 35 39 29 102 -7 69 -2 81 15 37 l11 -28 23 45 c32 61 31 73 -12 110 -114 100 -276 92 -375 -18 -42 -47 -63 -83 -89 -159 -10 -30 -28 -67 -40 -84 -22 -31 -94 -89 -111 -89 -4 0 -8 74 -8 165 0 91 3 165 6 165 3 0 14 -5 25 -10 17 -10 19 -23 19 -143 l1 -132 29 34 c25 30 30 44 32 105 3 68 4 70 17 44 l14 -27 23 50 c22 46 22 52 8 74 -17 27 -76 69 -117 84 -38 15 -140 14 -155 -1z m153 -22 c19 -8 51 -27 70 -42 50 -38 44 -69 -17 -88 -15 -4 -18 -17 -18 -71 0 -37 -4 -64 -9 -61 -5 3 -9 41 -9 83 0 43 -1 86 -1 95 -1 25 -58 53 -77 37 -19 -15 -21 -318 -2 -337 24 -24 57 -12 107 36 37 36 56 66 81 130 18 46 46 101 62 123 36 49 111 106 117 87 2 -7 10 -21 19 -30 14 -16 13 -18 -6 -18 -48 0 -103 -73 -151 -199 -26 -69 -84 -143 -133 -171 -48 -27 -161 -40 -173 -20 -5 9 3 22 24 39 l31 26 0 160 0 160 -31 26 c-19 15 -29 31 -25 37 10 17 100 15 141 -2z m487 -12 c18 -9 47 -30 65 -47 26 -24 30 -34 22 -49 -5 -10 -21 -18 -34 -18 -27 0 -33 -13 -38 -95 -2 -27 -4 -8 -5 44 -2 82 -5 98 -24 118 -25 27 -41 29 -62 7 -23 -23 -23 -315 0 -338 20 -20 20 -20 69 8 51 30 85 78 124 174 37 92 62 129 115 168 54 41 108 58 162 50 86 -11 172 -74 159 -116 -4 -13 -13 -20 -24 -18 -10 2 -25 -3 -34 -11 -15 -12 -17 -10 -17 22 0 27 -7 41 -27 57 -32 25 -54 23 -68 -6 -10 -21 -10 -21 -28 3 -22 28 -45 24 -91 -14 -46 -38 -81 -93 -106 -164 -41 -119 -116 -192 -215 -210 -87 -16 -126 9 -70 45 25 16 25 17 25 180 l0 164 -27 20 c-18 13 -24 24 -20 36 6 15 16 17 62 12 30 -3 70 -13 87 -22z m898 10 c2 -3 -9 -16 -25 -28 -30 -23 -30 -26 -33 -127 -2 -57 -5 -106 -8 -108 -2 -2 -4 43 -4 101 0 123 -9 139 -60 118 -46 -19 -112 -99 -134 -161 -25 -72 -68 -148 -103 -181 -85 -81 -235 -83 -312 -4 -25 25 -31 39 -26 55 3 12 14 21 24 21 28 0 41 21 43 70 1 26 4 11 7 -39 6 -77 8 -86 33 -104 27 -20 28 -20 48 -2 18 16 20 32 22 159 l2 141 6 -149 c6 -178 11 -185 85 -142 52 31 95 91 121 170 49 145 154 231 269 219 22 -3 42 -7 45 -9z m-1072 -380 c20 -10 21 -13 7 -24 -8 -7 -15 -19 -15 -27 0 -11 -6 -11 -30 4 -17 10 -42 30 -56 44 -22 23 -23 29 -13 52 7 15 17 23 25 20 28 -11 44 18 46 81 1 46 3 37 7 -39 6 -91 8 -100 29 -111z m912 44 c0 -55 51 -88 80 -53 11 13 16 12 41 -8 50 -39 30 -62 -44 -51 -51 8 -102 34 -139 69 -23 21 -26 29 -16 44 6 11 19 16 29 14 11 -3 21 1 25 11 9 24 24 9 24 -26z"/>
<path d="M470 550 c0 -65 3 -90 13 -90 9 0 11 23 9 90 -2 49 -8 90 -13 90 -5 0 -9 -40 -9 -90z"/>
<path d="M1090 551 l0 -89 33 1 c31 2 32 3 35 55 3 56 -10 85 -34 75 -10 -4 -14 2 -14 21 0 14 -4 26 -10 26 -6 0 -10 -36 -10 -89z m48 -27 c-2 -22 -7 -39 -13 -39 -12 0 -19 60 -10 83 10 28 27 -3 23 -44z"/>
<path d="M280 545 c0 -69 3 -85 15 -85 9 0 15 9 15 25 0 15 6 25 15 25 19 0 35 31 35 69 0 32 -22 51 -59 51 -20 0 -21 -6 -21 -85z m50 19 c0 -19 -4 -34 -10 -34 -5 0 -10 18 -10 41 0 24 4 38 10 34 6 -3 10 -22 10 -41z"/>
<path d="M612 618 c-7 -7 -12 -38 -12 -70 0 -45 5 -66 22 -88 21 -29 58 -41 58 -20 0 6 -7 10 -17 10 -15 0 -15 1 0 18 12 13 17 37 17 78 0 61 -11 84 -40 84 -9 0 -21 -5 -28 -12z m46 -85 c-5 -72 -28 -68 -28 5 0 32 3 62 7 66 13 13 24 -24 21 -71z"/>
<path d="M750 545 c0 -83 0 -85 24 -85 39 0 56 25 56 84 0 58 -19 86 -58 86 -21 0 -22 -4 -22 -85z m45 0 c0 -38 -4 -60 -12 -62 -10 -4 -13 13 -13 62 0 49 3 66 13 63 8 -3 12 -25 12 -63z"/>
<path d="M939 608 c-3 -53 3 -134 11 -142 5 -5 17 -5 27 -1 17 8 17 8 1 12 -25 6 -26 91 -2 100 15 6 15 7 -1 19 -9 7 -14 17 -10 23 3 6 -1 11 -9 11 -10 0 -17 -9 -17 -22z"/>
<path d="M392 591 c-19 -11 -27 -83 -13 -110 15 -26 47 -27 61 -2 15 29 12 87 -6 105 -18 18 -24 19 -42 7z m28 -61 c0 -27 -4 -50 -10 -50 -5 0 -10 23 -10 50 0 28 5 50 10 50 6 0 10 -22 10 -50z"/>
<path d="M510 588 c0 -7 7 -40 15 -73 12 -52 12 -61 0 -71 -20 -15 -19 -24 5 -24 19 0 28 22 45 110 4 19 9 43 11 53 4 11 0 17 -10 17 -11 0 -16 -9 -16 -29 0 -16 -3 -38 -7 -48 -6 -13 -9 -6 -13 26 -3 25 -11 46 -17 49 -7 2 -13 -2 -13 -10z"/>
<path d="M852 588 c-13 -13 -16 -38 -6 -38 4 0 13 8 20 18 12 16 13 16 20 -2 5 -13 3 -21 -4 -24 -24 -8 -43 -35 -40 -56 2 -16 11 -21 36 -23 l32 -1 0 63 c0 48 -4 64 -16 69 -22 8 -28 8 -42 -6z m38 -88 c0 -19 -11 -26 -23 -14 -8 8 3 34 14 34 5 0 9 -9 9 -20z"/>
<path d="M1006 584 c-20 -20 -20 -34 -1 -34 8 0 15 7 15 15 0 8 5 15 10 15 19 0 10 -31 -16 -54 -37 -31 -26 -66 20 -66 l33 0 -4 58 c-3 31 -6 63 -8 70 -6 17 -30 15 -49 -4z m34 -84 c0 -11 -4 -20 -10 -20 -5 0 -10 9 -10 20 0 11 5 20 10 20 6 0 10 -9 10 -20z"/>
<path d="M1193 593 c-13 -5 -18 -43 -7 -43 4 0 13 8 20 18 12 16 13 16 14 0 0 -9 -11 -29 -25 -42 -33 -33 -21 -65 25 -64 30 1 30 2 30 58 0 69 -16 90 -57 73z m23 -110 c-11 -11 -19 6 -11 24 8 17 8 17 12 0 3 -10 2 -21 -1 -24z"/>
<path d="M1271 581 c-8 -15 -5 -27 15 -56 25 -37 26 -65 0 -30 -9 13 -15 15 -20 6 -11 -17 14 -42 38 -39 29 4 32 35 7 69 -12 15 -21 34 -21 41 1 8 5 7 14 -4 17 -23 26 -23 26 1 0 17 -18 31 -40 31 -5 0 -14 -9 -19 -19z"/>
<path d="M1362 588 c-7 -7 -12 -36 -12 -65 0 -57 17 -76 48 -56 22 13 27 33 8 33 -9 0 -16 -4 -16 -10 0 -5 -4 -10 -10 -10 -5 0 -10 9 -10 20 0 15 7 20 25 20 21 0 25 5 25 28 0 29 -16 52 -35 52 -6 0 -16 -5 -23 -12z m38 -40 c0 -5 -7 -8 -15 -8 -15 0 -20 21 -8 33 7 7 23 -11 23 -25z"/>
</g>
</svg>
    <p> &copyPolyQ Database. All rights reserved 2021-2022. Authors mentioned and database creators all accounted for.</p>
    <div class="logos">
      <a class="logo-one" href=""> <img src="../../Images/Logo_ABCRI.png" alt=""></a>
      <a class="logo-two" href=""> <img src="../../Images/Logo_MNGT.png" alt=""></a>
      <a class="logo-three" href=""> <img src="../../Images/fmcb-mod.png" alt=""></a>
    </div>
  </footer>
  <script src="../../Scripts/jquery-3.6.0.min.js"></script>
  <script type="text/javascript" src="https://cdn.jsdelivr.net/npm/interactiveimagejs@2.7.1/dist/interactive-image.min.js"></script>
  <script src="../../Scripts/Image-Int-Scripts/image-int-sca17.js"></script>
  <script>
            var indicator = document.getElementById('indicator');

            var spy = new ScrollSpy(
                {
                    contexts_class: 'scrollspy'
                }
            );

            spy.Indicator({
                element: indicator
            });
</script>
<script>
/* When the user clicks on the button,
toggle between hiding and showing the dropdown content */
function myFunction() {
  document.getElementById("myDropdown").classList.toggle("show");
}

function myFunctionLittle() {
  document.getElementById("myDropdownLittle").classList.toggle("show");
}

// Close the dropdown if the user clicks outside of it
window.onclick = function(event) {
  if (!event.target.matches('.dropbtn')) {
    var dropdowns = document.getElementsByClassName("dropdown-content");
    var i;
    for (i = 0; i < dropdowns.length; i++) {
      var openDropdown = dropdowns[i];
      if (openDropdown.classList.contains('show')) {
        openDropdown.classList.remove('show');
      }
    }
  }
  if (!event.target.matches('.dropbtn-little')){
    var dropLittle = document.getElementsByClassName("dropdown-content-little");
    var r;
    for (r = 0; r < dropLittle.length; r++) {
      var openDropLittle = dropLittle[r];
      if (openDropLittle.classList.contains('show')) {
        openDropLittle.classList.remove('show');
      }
    }
  }
}

</script>
<script>


$(document).scroll(function() {
    checkOffset();
});

function checkOffset() {
    if($('#bar-right').offset().top + $('#bar-right').height() >= $('#references').offset().top + 200)
          $('#bar-right').hide(800);
    if($(document).scrollTop() + window.innerHeight < $('#references').offset().top + 200)
          $('#bar-right').show(800); // restore when you scroll up
}
</script>
<script>

function reload(){
  var imageInt = document.getElementById("my-interactive-image");
  var imageContent = imageInt.innerHTML;
  imageInt.innerHTML = imageContent;
}

</script>

</body>


</html>
